Astrazeneca Pharma India Ltd (ASTRAZEN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 777011,
    "name": "Astrazeneca Phar",
    "stock_name": "Astrazeneca Phar",
    "full_name": "Astrazeneca Pharma India Ltd",
    "name_url": "stocks-analysis/astrazeneca-phar",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "9,091.00",
    "chg": -135.5,
    "chgp": "-1.47%",
    "dir": -1,
    "prev_price": "9,226.50",
    "mcapval": "22,727.50 Cr",
    "mcap": "Small Cap",
    "scripcode": 506820,
    "symbol": "ASTRAZEN",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE203A01020",
    "curr_date": "Dec 08",
    "curr_time": "",
    "bse_nse_vol": "2.04 k",
    "exc_status": "Active",
    "traded_date": "Dec 08, 2025",
    "traded_date_str": "2025 12 08",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astrazeneca-phar-777011-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MN",
      "url": "https://www.marketsmojo.com/mojopro/strategy/2",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astrazeneca-phar-777011-1&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Astrazeneca Phar Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-phar-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3738001",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AstrazenecaPhar_mojoScore_3738001.png",
        "date": "2025-12-01 10:09:27",
        "description": "Astrazeneca Phar has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of strong operational fundamentals alongside valuation concerns, prompting a reassessment of its standing within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Astrazeneca Phar technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrazeneca-phar-technically-bullish-or-bearish-3684064",
        "imagepath": "",
        "date": "2025-11-10 08:11:15",
        "description": "As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD readings indicating bullish momentum. The Bollinger Bands and moving averages also reflect a mildly bullish outlook on the daily time frame. However, the KST shows a mixed signal with a bullish weekly but mildly bearish monthly reading. The Dow Theory aligns with a mildly bullish stance on both weekly and monthly charts. Despite recent price declines, the longer-term returns remain strong, particularly over 3 years and 5 years, indicating resilience in the stock...."
      },
      {
        "title": "Astrazeneca Pharma India Shows Strong Financial Performance Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-stock-downgraded-from-buy-to-hold-by-marketsmojo-3684586",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstrazenecaPhar_mojoScore_3684586.png",
        "date": "2025-11-10 08:10:25",
        "description": "Astrazeneca Pharma India has recently experienced a change in its evaluation, influenced by shifts in technical indicators. The company has shown strong financial performance, with a year-to-date return of 23.77% and a notable profit growth of 35.70% in the last six months, outperforming the BSE500 index consistently."
      },
      {
        "title": "AstraZeneca Pharma India Faces Mixed Technical Trends Amid Strong Long-Term Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrazeneca-pharma-indias-technical-trend-changes-from-bullish-to-mildly-bullish-amid-price-decline-3684454",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstrazenecaPhar_technicaldot_3684454.png",
        "date": "2025-11-10 08:04:08",
        "description": "AstraZeneca Pharma India has recently revised its evaluation amid current market dynamics, with its stock priced at 9,078.70. Over the past year, it has achieved a return of 20.97%, significantly outperforming the Sensex. The technical outlook presents mixed signals, indicating cautious optimism in its performance."
      },
      {
        "title": "How has been the historical performance of Astrazeneca Phar?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-astrazeneca-phar-3683498",
        "imagepath": "",
        "date": "2025-11-09 22:40:02",
        "description": "Answer:\nThe historical performance of Astrazeneca Phar shows a significant growth trend in net sales and profits over the years, with net sales reaching 1,716.29 Cr in March 2025, up from 1,295.53 Cr in March 2024 and 1,002.97 Cr in March 2023. The total operating income followed a similar trajectory, increasing to 1,716.29 Cr in March 2025 from 1,295.53 Cr in March 2024. However, total expenditure also rose to 1,462.32 Cr in March 2025, compared to 1,111.08 Cr in March 2024, leading to an operating profit of 294.60 Cr in March 2025, up from 219.25 Cr in March 2024. Profit before tax decreased to 156.36 Cr in March 2025 from 219.54 Cr in March 2024, while profit after tax was 115.74 Cr in March 2025, down from 161.51 Cr in March 2024. The earnings per share (EPS) also saw a decline to 46.3 in March 2025 from 64.6 in March 2024. \n\nIn terms of assets and liabilities, total assets increased to 1,476.56 Cr in M..."
      },
      {
        "title": "Is Astrazeneca Phar technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrazeneca-phar-technically-bullish-or-bearish-3682940",
        "imagepath": "",
        "date": "2025-11-09 08:11:36",
        "description": "As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the weekly MACD and KST indicators both showing bullish signals, while the monthly KST is mildly bearish, indicating some caution. The RSI shows no signal on both weekly and monthly time frames, suggesting a lack of momentum. Moving averages on the daily time frame are mildly bullish, and Bollinger Bands are also indicating a mildly bullish trend on both weekly and monthly levels. Dow Theory confirms a mildly bullish stance across both time frames. Overall, while the trend is mildly bullish, the mixed signals from the KST and RSI suggest a cautious approach...."
      },
      {
        "title": "Are Astrazeneca Phar latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-astrazeneca-phar-latest-results-good-or-bad-3682424",
        "imagepath": "",
        "date": "2025-11-08 19:18:46",
        "description": "AstraZeneca Pharma India has reported its financial results for Q2 FY26, showcasing a notable revenue growth of 35.81% year-on-year, with net sales reaching ₹526.31 crores. This marks a continuation of a strong revenue trajectory, as the company has achieved sequential growth for seven consecutive quarters. The quarter-on-quarter growth was 9.54%, building upon the previous quarter's performance. \n\nHowever, the profitability metrics indicate some challenges. The net profit for the quarter was ₹55.83 crores, reflecting a sequential decline of 4.15%. Additionally, the operating margin, excluding other income, contracted to 15.41%, down 257 basis points from the prior quarter. This decline in margins suggests that while revenue growth is robust, the company is facing pressures related to costs, particularly in employee expenses and overall cost structure management.\n\nOn a half-yearly basis, AstraZeneca Pharma ..."
      },
      {
        "title": "Is Astrazeneca Phar technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrazeneca-phar-technically-bullish-or-bearish-3682125",
        "imagepath": "",
        "date": "2025-11-08 08:15:08",
        "description": "As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and mildly bullish signals from Bollinger Bands and moving averages on the daily time frame. The KST shows a bullish weekly signal but is mildly bearish monthly, indicating mixed strength. The Dow Theory aligns with a mildly bullish outlook on both weekly and monthly charts. Overall, while there are some positive indicators, the shift to mildly bullish suggests caution in the current momentum...."
      },
      {
        "title": "AstraZeneca Pharma India Q2 FY26: Strong Revenue Growth Masks Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/astrazeneca-pharma-india-q2-fy26-strong-revenue-growth-masks-profitability-concerns-3680840",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstrazenecaPhar_quaterlyResult_3680840.png",
        "date": "2025-11-07 21:47:36",
        "description": "AstraZeneca Pharma India Ltd. delivered a mixed performance in Q2 FY26, with robust revenue expansion overshadowed by margin compression and a sequential decline in profitability. The pharmaceutical major reported net sales of ₹526.31 crores for the quarter ended June 2025, marking a healthy 9.54% quarter-on-quarter increase and an impressive 35.81% year-on-year surge. However, net profit stood at ₹55.83 crores, declining 4.15% sequentially from ₹58.25 crores in Q1 FY26, though still recovering substantially from the loss of ₹11.79 crores recorded in the corresponding quarter last year."
      }
    ],
    "total": 336,
    "sid": "777011",
    "stock_news_url": "https://www.marketsmojo.com/news/astrazeneca-pharma-india-777011"
  },
  "announcements": [
    {
      "details": "AstraZeneca Pharma India Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "AstraZeneca Pharma India Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "05-Dec-2019"
    },
    {
      "details": "AstraZeneca Pharma India Limited has informed the Exchange a copy of disclosure of Related Party Transactions for half year ended September 30, 2019 under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended",
      "source": "NSE",
      "caption": "AstraZeneca Pharma India Limited - Other General Purpose",
      "datetime": "27-Nov-2019"
    },
    {
      "details": "AstraZeneca Pharma India Limited has informed the Exchange regarding 'Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on November 13, 2019 in respect of the Unaudited Financial Results for the quarter ended September 30, 2019 approved in the Board Meeting of the Company held on November 11, 2019. '.",
      "source": "NSE",
      "caption": "AstraZeneca Pharma India Limited - Updates",
      "datetime": "15-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Astrazeneca Pharma India Ltd has declared <strong>1600%</strong> dividend, ex-date: 18 Jul 25",
          "dt": "2025-07-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Astrazeneca Pharma India Ltd has announced <strong>2:10</strong> stock split, ex-date: 15 Jun 06",
          "dt": "2006-06-15",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Astrazeneca Phar Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-12-01 10:09:27

Astrazeneca Phar has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of strong operational fundamentals alongside valuation concerns, prompting a reassessment of its standing within the Pharmaceuticals & Biotechnology sector.

Is Astrazeneca Phar technically bullish or bearish?

2025-11-10 08:11:15

As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD readings indicating bullish momentum. The Bollinger Bands and moving averages also reflect a mildly bullish outlook on the daily time frame. However, the KST shows a mixed signal with a bullish weekly but mildly bearish monthly reading. The Dow Theory aligns with a mildly bullish stance on both weekly and monthly charts. Despite recent price declines, the longer-term returns remain strong, particularly over 3 years and 5 years, indicating resilience in the stock....

Astrazeneca Pharma India Shows Strong Financial Performance Amid Mixed Technical Signals

2025-11-10 08:10:25

Astrazeneca Pharma India has recently experienced a change in its evaluation, influenced by shifts in technical indicators. The company has shown strong financial performance, with a year-to-date return of 23.77% and a notable profit growth of 35.70% in the last six months, outperforming the BSE500 index consistently.

AstraZeneca Pharma India Faces Mixed Technical Trends Amid Strong Long-Term Performance

2025-11-10 08:04:08

AstraZeneca Pharma India has recently revised its evaluation amid current market dynamics, with its stock priced at 9,078.70. Over the past year, it has achieved a return of 20.97%, significantly outperforming the Sensex. The technical outlook presents mixed signals, indicating cautious optimism in its performance.

How has been the historical performance of Astrazeneca Phar?

2025-11-09 22:40:02

Answer: The historical performance of Astrazeneca Phar shows a significant growth trend in net sales and profits over the years, with net sales reaching 1,716.29 Cr in March 2025, up from 1,295.53 Cr in March 2024 and 1,002.97 Cr in March 2023. The total operating income followed a similar trajectory, increasing to 1,716.29 Cr in March 2025 from 1,295.53 Cr in March 2024. However, total expenditure also rose to 1,462.32 Cr in March 2025, compared to 1,111.08 Cr in March 2024, leading to an operating profit of 294.60 Cr in March 2025, up from 219.25 Cr in March 2024. Profit before tax decreased to 156.36 Cr in March 2025 from 219.54 Cr in March 2024, while profit after tax was 115.74 Cr in March 2025, down from 161.51 Cr in March 2024. The earnings per share (EPS) also saw a decline to 46.3 in March 2025 from 64.6 in March 2024. In terms of assets and liabilities, total assets increased to 1,476.56 Cr in M...

Is Astrazeneca Phar technically bullish or bearish?

2025-11-09 08:11:36

As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the weekly MACD and KST indicators both showing bullish signals, while the monthly KST is mildly bearish, indicating some caution. The RSI shows no signal on both weekly and monthly time frames, suggesting a lack of momentum. Moving averages on the daily time frame are mildly bullish, and Bollinger Bands are also indicating a mildly bullish trend on both weekly and monthly levels. Dow Theory confirms a mildly bullish stance across both time frames. Overall, while the trend is mildly bullish, the mixed signals from the KST and RSI suggest a cautious approach....

Are Astrazeneca Phar latest results good or bad?

2025-11-08 19:18:46

AstraZeneca Pharma India has reported its financial results for Q2 FY26, showcasing a notable revenue growth of 35.81% year-on-year, with net sales reaching ₹526.31 crores. This marks a continuation of a strong revenue trajectory, as the company has achieved sequential growth for seven consecutive quarters. The quarter-on-quarter growth was 9.54%, building upon the previous quarter's performance. However, the profitability metrics indicate some challenges. The net profit for the quarter was ₹55.83 crores, reflecting a sequential decline of 4.15%. Additionally, the operating margin, excluding other income, contracted to 15.41%, down 257 basis points from the prior quarter. This decline in margins suggests that while revenue growth is robust, the company is facing pressures related to costs, particularly in employee expenses and overall cost structure management. On a half-yearly basis, AstraZeneca Pharma ...

Is Astrazeneca Phar technically bullish or bearish?

2025-11-08 08:15:08

As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and mildly bullish signals from Bollinger Bands and moving averages on the daily time frame. The KST shows a bullish weekly signal but is mildly bearish monthly, indicating mixed strength. The Dow Theory aligns with a mildly bullish outlook on both weekly and monthly charts. Overall, while there are some positive indicators, the shift to mildly bullish suggests caution in the current momentum....

AstraZeneca Pharma India Q2 FY26: Strong Revenue Growth Masks Profitability Concerns

2025-11-07 21:47:36

AstraZeneca Pharma India Ltd. delivered a mixed performance in Q2 FY26, with robust revenue expansion overshadowed by margin compression and a sequential decline in profitability. The pharmaceutical major reported net sales of ₹526.31 crores for the quarter ended June 2025, marking a healthy 9.54% quarter-on-quarter increase and an impressive 35.81% year-on-year surge. However, net profit stood at ₹55.83 crores, declining 4.15% sequentially from ₹58.25 crores in Q1 FY26, though still recovering substantially from the loss of ₹11.79 crores recorded in the corresponding quarter last year.

View All News